Strategies to maximize treatment success in moderate to severe psoriasis: Establishing treatment goals and tailoring of biologic therapies

Seminars in Cutaneous Medicine and Surgery

Volumn 33, Issue 2, 2014, Pages 91-97

  Brezinski, Elizabeth A ^a   Armstrong, April W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; APREMILAST; BRODALUMAB; DRUG ANTIBODY; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; IXEKIZUMAB; PLACEBO; SECUKINUMAB; TOFACITINIB; USTEKINUMAB; ANTIBODY; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BIOLOGICAL THERAPY; BODY WEIGHT; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HEALTH CARE MANAGEMENT; HEPATITIS C; HUMAN; LEUKOENCEPHALOPATHY; LOADING DRUG DOSE; OBESITY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SAFETY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; TREATMENT OUTCOME; TREATMENT PLANNING; BLOOD; DRUG RESISTANCE; IMMUNOLOGY; LIVER DISEASE; MEDICATION COMPLIANCE; MOLECULARLY TARGETED THERAPY; MOTIVATION; PATIENT PARTICIPATION; REVIEW; SEVERITY OF ILLNESS INDEX;

ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; DRUG RESISTANCE; GOALS; HUMANS; INDIVIDUALIZED MEDICINE; LIVER DISEASES; MEDICATION ADHERENCE; MOLECULAR TARGETED THERAPY; OBESITY; PATIENT PARTICIPATION; PATIENT PREFERENCE; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84907933714     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.12788/j.sder.0086     Document Type: Article

References (58)

1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis Prevalence among Adults in the United States. J Am Acad Dermatol. In press.
2. Pariser DM, Bagel J, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007;143(2):239-242.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-174.
5. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115.
6. Armstrong AW, D. RA, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185.
7. Mrowietz U, Kragballe K, Nast A, Reich K. Strategies for improving the quality of care in psoriasis with the use of treatment goals-a report on an implementation meeting. J Eur Acad Dermatol Venereol. 2011;25(Suppl 3):1-13.
8. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10.
9. Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013;54(2):148-154.
10. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. JAMA Dermatol. 2012;148(1):95-102.
11. Puig L, Bordas X, Carrascosa JM, et al. Consensus document on the evaluation and treatment of moderate to severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology[in Spanish]. Actas Dermosifiliogr. 2009;100(4):277-286.
12. Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210-219.
13. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139(6):719-727.
14. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-566.
15. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014-2022.
16. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate to severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-1374.
17. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-1674.
18. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-1189.
19. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-1199.
20. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-421.
21. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebocontrolled dose-ranging study. Br J Dermatol. 2012;167(3):668-677.
22. Papp KA, Kaufmann R, Thaci D, Hu C, Sutherland D, Rohane P. (2012). Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study [published online ahead of print]. J Eur Acad Dermatol Venerol. doi: 10.1111/j.1468-3083.2012.04716.x.
23. Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148(4):487-494.
24. Molteni S, Reali E. Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis. Psoriasis: Targets and Therapy. 2012;2:55-66.
25. Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. A2013;72:(Suppl2): ii104-110.
26. Humira (adalimumab) prescribing information [package insert], Inventor. North Chicago, IL. Abbott Laboratories, 2013.
27. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448-456.
28. Armstrong AW, Bao Y, Signorovitch J, Samuelson T, Sundaram M, Mulani PM. Comparison of benefit-risk profiles with adalimumab vs etanercept treatment for moderate to severe psoriasis, stratified by weight. Paper presented at: 20th Congress of the European Academy of Dermatology and Venereology; October 20-24, 3011; Lisbon, Portugal.
29. Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One. 2012;7(4):e33486.
30. Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167(3):658-667.
31. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675-1684.
32. Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol. 2008;7(3):245-253.
33. Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol. 2011;164(6):1383-1386.
34. Bagel J. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis. J Drugs Dermatol. 2011;10(4):366-371.
35. Wolf P, Hofer A, Weger W, Posch-Fabian T, Gruber-Wackernagel A, Legat FJ. 311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed. 2011;27(4):186-189.
36. Park KK, Wu JJ, Koo J. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NBUVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol. 2013;27(7):899-906.
37. Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol. 2009;160(1):186-189.
38. Lynde CW, Gupta AK, Guenther L, Poulin Y, Levesque A, Bissonnette R. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat. 2012;23(4):261-267.
39. De Simone C, D'Agostino M, Capizzi R, Capponi A, Venier A, Caldarola G. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. Eur J Dermatol. 2011;21(4):568-572.
40. Wolf P, Weger W, Legat FJ, et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol. 2012;166(1):147-153.
41. Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebocontrolled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649-657.
42. Driessen RJ, van de Kerkhof PCM, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol. 2008;159(2):460-463.
43. Zachariae C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88(5):495-501.
44. Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008;158(6):1345-1349.
45. Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol. 2008;47(5):514-518.
46. Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149(7):785-801.
47. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460-1468.
48. Hsu L, Armstrong AW. Antidrug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;9(10):949-958.
49. Hsu L, Snodgrass BT, Armstrong AW. (2013). Antidrug Antibodies in Psoriasis: A Systematic Review [published online ahead of print]. Br J Dermatol. doi: 10.1111/bjd.12654.
50. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552-1563.
51. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45.
52. Schaarschmidt ML, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. JAMA Dermatol. 2011;147(11):1285-1294.
53. Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27(2):187-198.
54. Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27-33.
55. Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(3):459-477.
56. Frankel AJ, Van Voorhees AS, Hsu S, et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;61(6):1044-1055.
57. Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis. J Am Acad Dermatol. 2013;69(6):1003-1013.
58. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50(9):1700-1711.